Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Kessler
Robert M
RM
D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000068180:Aripiprazole; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000517:prevention & control; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use*; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D058830:Serotonin 5-HT2 Receptor Antagonists; D009435:Synaptic Transmission / Q000187:drug effects*
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D058830:Serotonin 5-HT2 Receptor Antagonists; D000068180:Aripiprazole; D006220:Haloperidol